Immuneering Corporation Overview
Pro stress-test →Immuneering is a late-stage clinical oncology company advancing Deep Cyclic MEK inhibition. The company leverages artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies.
Strategic Profile
Pro stress-test →The lead product candidate IMM-1-104, a dual-MEK inhibitor, is in Phase 1/2a clinical trial for treating patients with cancer including pancreatic, melanoma, and non-small cell lung cancer caused by RAS and/or RAF mutations. Recent Phase 2a data announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib combined with mGnP.
Competitive Landscape
Pro stress-test →Immuneering competes in the clinical-stage oncology space developing medicines for broad cancer populations. Key competitors include established biotech firms with RAS-focused programs (Rgenix, Revolution Medicines) and larger pharmaceutical companies with MEK inhibitor portfolios. Immuneering's AI-driven RABIT platform and exceptional pancreatic cancer data provide differentiation, though clinical validation and regulatory approval timelines remain competitive risks.
Industry Context
Immuneering Corporation operates in Biopharmaceuticals / Clinical-Stage Oncology.
Key facts
Founded: 2008 · Headquarters: Cambridge, MA · Employees: 66 · Market cap: $338.35M